Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma
| Autor: | Thomas Vogt, Nathalie Krecké, Anna Zimmer, Bettina Friesenhahn-Ochs, Claudia Pföhler, Cornelia S. L. Müller |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
vitiligo
medicine.medical_specialty Endocrinology Diabetes and Metabolism medicine.medical_treatment Ipilimumab Dermatology Vitiligo medicine.disease_cause Autoimmunity immunology 03 medical and health sciences 0302 clinical medicine melanoma Medicine ipilimumab Adverse effect Autoimmune disease biology business.industry Melanoma autoimmunity Immunotherapy medicine.disease side effects 030220 oncology & carcinogenesis 030221 ophthalmology & optometry biology.protein orbital myositis Antibody business Research Paper medicine.drug |
| Zdroj: | Dermato-endocrinology |
| ISSN: | 1938-1980 |
| Popis: | Ipilimumab is an anti-CTLA-4 antibody that is approved for the treatment of metastatic malignant melanoma. Side-effects are mostly immune-mediated and in many cases the lack of specific symptoms leads to delayed diagnosis and treatment of adverse events. We present the case of a female patient who experienced an uncommon combination of adverse reactions while undergoing therapy with ipilimumab and where the absence of specificity of the symptoms led to late diagnosis and treatment of side effects. Autoimmune disease was neither associated with tumor response nor with prolonged survival. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|